Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Kondo M, Simon MS, Westblade LF, Jenkins SG, N Babady E, Loo AS, et al. Implementation of infectious diseases rapid molecular diagnostic tests and antimicrobial stewardship program involvement in acute-care hospitals. Infect Control Hosp Epidemiol. 2021;42(5):609-611.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2021.

Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021;4(3):e214302.

D'Alfonso TM, Pareja F, Paula AD, Vahdatinia M, Gazzo A, Ferrando L, et al. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. J Pathol Clin Res. 2021;7(2):113-120.

Mitchell KF, McElvania E, Wallace MA, Droske LE, Robertson AE, Westblade LF, et al. Evaluating the Rapid Emergence of Daptomycin Resistance in : a Multicenter Study. J Clin Microbiol. 2021;59(4).

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).

Satlin MJ, Zucker J, Baer BR, Rajan M, Hupert N, Schang LM, et al. Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. PLoS One. 2021;16(11):e0257979.

Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, et al. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nat Commun. 2021;12(1):6377.

Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, A Crowson N, et al. Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol. 2021;50:151645.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.